Finance & Acquisitions: Acceleron

Parents

$30m Series B (2006)
2011: Acceleron Pharma raises $30M Celgene strategic financing (2011)
2011: Acceleron Pharma Secures $30 Million Private Financing (2011)
2021: Merck, wading even further into rare disease, inks $11.5B deal for Acceleron and its potential PAH blockbuster
Acceleron Awarded Grants from the Qualifying Therapeutic Discovery Project Program (2010)
Acceleron has raised about $86 million in venture capital and is working with Celgene Corp. to develop a bone-forming drug to tr
Acceleron Pharma Completes $31M Series C Financing(2007)
Acceleron Pharma, Developing Drugs to Treat Musculoskeletal and Metabolic Disorders, Secures $25 Million in Series A Funding (2004)
Acceleron: Venture Investors
Iinvestors include Celgene, Advanced Technology Ventures, Avalon Ventures, Bessemer Venture Partners, Flagship Ventures, Polaris Venture Partners, MPM BioEquities, OrbiMed Advisors, QVT Financial, Sutter Hill Ventures and Venrock.
It has three drugs in trials:
Revenue (2018): $14 million
Revenue (2019): $74 million